In our clinical work, we encounter many patients and friends who understand rheumatic diseases only as joint and muscle pains, and think that there is no big problem, so they usually buy some medicines and prescriptions first, and come to the hospital only when it doesn’t work, often missing the best time for treatment. In fact, rheumatologic diseases are a large group of diseases, including diffuse connective tissue diseases (systemic lupus erythematosus, dry syndrome, rheumatoid arthritis, scleroderma, polymyositis/dermatomyositis, vasculitis, etc.); spondyloarthropathies (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, etc.); osteoarthritis and soft tissue diseases and more than a hundred other diseases, not only joint lesions, but also multi-organ and multi-system involvement, with complex clinical manifestations. The clinical manifestations are complex, and the lesions are multidisciplinary, making them easy to misdiagnose and underdiagnose. They are highly prevalent and disabling, affecting the workforce and quality of life, and causing a burden to society and families. For these diseases that require systematic treatment, going to the rheumatology department of a regular hospital is the most secure choice. Rheumatoid arthritis (RA) is a type of systemic autoimmune disease with symmetrical polyarthritis as its main manifestation, with patients all over the world. The most common clinical symptom is joint symptoms, which are usually characterized by recurrent symmetrical joint swelling and pain with morning stiffness, and joint deformity and dysfunction if left untreated. Extra-articular manifestations may also occur, including rheumatoid nodules, vasculitis, interstitial lung disease and damage to the heart, nervous system, blood system and other systems. Laboratory tests related to RA: blood count may be mild to moderate anemia, and platelets may be elevated in active patients; sedimentation and C-reactive protein are often elevated and correlate with disease activity; rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies are positive, and their titers are generally proportional to disease activity and severity; X-ray or MRI of joints are important for RA diagnosis, joint lesion staging, and lesion progression monitoring. The joint X-ray or MRI is important for the diagnosis of RA, staging of joint lesions, and monitoring of lesion progression. The principles of treatment for rheumatoid arthritis are early treatment, combination of drugs, individualized treatment and functional exercise, as well as monitoring and reducing the adverse effects of drugs, reducing joint pain and inflammation, protecting joint function and improving quality of life. The main drugs used in the treatment of rheumatoid arthritis are non-steroidal anti-inflammatory drugs, slow-acting anti-rheumatic drugs, glucocorticoids, biological agents and traditional Chinese medicine. Once diagnosed, each patient should be treated as early as possible: NSAIDs can be used to relieve joint swelling and pain, and slow-acting anti-rheumatic drugs should be applied in a timely manner to control the development of the disease in order to prevent joint deformity and dysfunction. At the same time, it is also necessary to choose an individualized treatment plan for patients with the best therapeutic effect and no significant adverse effects. Non-steroidal anti-inflammatory drugs have analgesic and swelling effects and are commonly used to improve arthritis symptoms, but they cannot control the progression of the disease and must be taken together with slow-acting anti-rheumatic drugs, such as celecoxib, meloxicam and diclofenac sodium, etc. In the process of use, attention must be paid to gastrointestinal and cardiovascular adverse reactions and avoid taking more than two such drugs at the same time. Slow-acting antirheumatic drugs are slow to work, and it takes about 1-6 months for clinical symptoms to improve and delay the effect of the disease. In general, a combination of slow-acting antirheumatic drugs should be used as early as possible in patients with more than 20 joints involved, joint bone destruction within 2 years of disease onset, persistently high rheumatoid factor titers, and extra-articular symptoms. Commonly used drugs include methotrexate (MTX), salazosulfapyridine (SSZ), hydroxychloroquine (HCQ), leflunomide (LEF), etc. Each slow-acting antirheumatic drug has its own different mechanism of action and adverse effects, which need to be carefully monitored during the drug use, such as regular review of blood and urine routine, liver and kidney function, etc. Glucocorticosteroids have powerful anti-inflammatory effects and can be given as short-acting hormones during acute attacks of arthritis, the dose of which is adjusted according to the severity of the disease and should generally not exceed 10 mg of prednisone per day. long-term use of glucocorticosteroids can cause dependence and make discontinuation difficult, and many adverse effects such as osteoporosis, hypertension and hyperglycemia can occur. Intra-articular hormone injections are beneficial in reducing arthritic symptoms and improving joint function, but should not be given more than three times in a year. Biological agents include TNF-α antagonists, IL-1 antagonists, CD20 monoclonal antibodies, etc., which have been gradually used at home and abroad in recent years. A large number of clinical results show that they can rapidly and effectively control symptoms, and bone destruction can be significantly inhibited in most patients after one year of use, with good anti-inflammatory and bone destruction prevention effects. The commonly used ones include etanercept, infliximab, adalimumab, anabolic acid, rituximab, etc. Active tuberculosis, hepatitis B, etc. need to be excluded when applied, and long-term use may increase the prevalence of lymphatic system tumors. Commonly used Chinese medicines include Leigongteng, Zhengqing Fengguo Ning, Pafulin (total glucoside of peony), etc. They have certain immunomodulatory effects and can improve clinical symptoms. Patients with advanced RA can be treated by surgical procedures including joint replacement and synovectomy. The indications are: severe joint deformity affecting daily life, nerve compression or tendon rupture or potential risk of the above; in addition, patients with juvenile rheumatoid arthritis should preferably wait for epiphyseal closure and be able to better cooperate with postoperative rehabilitation before surgery. In the process of treatment and rehabilitation of RA, we patients first need to build up confidence in the regular treatment and be a standardized patient. With the development of modern medicine, people have more understanding of RA, and have established scientific treatment concepts and treatment norms such as early treatment, standard treatment, coexistence with the disease, etc. New treatment drugs and treatment means have also been developed, and through standardized treatment, RA patients can fully resume normal work and life. RA is a disease that requires long-term follow-up, and sometimes a safe and effective treatment plan is often the result of several adjustments. During the course of treatment, follow up on time and do not change the treatment plan on your own. Most RA patients have prolonged disease, but aggressive, correct treatment can lead to remission in 60-90% of RA patients within one year.